Home › Compare › ENEKF vs ABBV
ENEKF yields 7.38% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ENEKF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENEKF + ABBV for your $10,000?
Enea AB (publ) provides software products for telecommunication, cybersecurity, medical device, and aerospace industries worldwide. It offers 5G data management products, such as Enea Stratum Network Data Layer, Enea Unified Data Manager, Enea Digital Identity, and Enea Equipment Identity Register; and access management and policy control services, including Enea Access Manager, Enea Policy Manager, and Enea ENUM. The company also provides traffic management services comprising Enea Video Optimization, Enea DPI and Content Filtering, Enea Integra NFV Platform, Encrypted Video Management, Enea TCP Acceleration, Enea Traffic Classifier, and Enea IP Traffic Filtering; and Enea Edge, a virtualization and management platform designed for deployment on any white-box uCPE, and optimized for common uCPE networking and edge use cases, such as SD-WAN, security, IoT, and 5G. In addition, the company offers Qosmos ixEngine, a deep packet inspection software; Qosmos Probe, a network sensor for granular visibility into network activity; Aptilo SMP Venue Wi-Fi Manager; and Zero-touch Wi-Fi IoT and Cellular IoT Connectivity services. Further, it provides Enea OSE, a real-time operating system for multi-processor systems; Enea Linux, a carrier-grade Linux for networking and real-time applications; and Enea OSEck, an operating system for high-performance and memory constrained applications. Additionally, it offers Enea Netbricks, a collection of highly portable networking protocols; Enea Element High Availability, an application development framework that simplifies the design and implementation of applications; and Enea Polyhedra, a SQL database, as well as software development and training services. Enea AB (publ) was founded in 1968 and is headquartered in Kista, Sweden.
Full ENEKF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.